Previous Article | Next Article 
Journal of Clinical Microbiology, October 1999, p. 3187-3193, Vol. 37, No. 10
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Comparison of Enzyme Immunoassay and Reverse
Transcriptase PCR for Identification of Serotype G9
Rotaviruses
Barbara S.
Coulson,1,*
Jon R.
Gentsch,2
Bimal K.
Das,3
M. K.
Bhan,3 and
Roger I.
Glass2
Department of Microbiology and Immunology,
the University of Melbourne, Parkville 3052, Victoria,
Australia1; the Viral Gastroenteritis
Section, Division of Viral and Rickettsial Diseases, National Center
for Infectious Diseases, Centers for Disease Control and Prevention,
Atlanta, Georgia 303332; and Department of
Paediatrics and Microbiology, Division of Gastroenterology and
Enteric Infections, All India Institute of Medical Sciences, Ansari
Nagar, New Delhi 11029, India3
Received 14 December 1998/Returned for modification 20 March
1999/Accepted 26 June 1999
 |
ABSTRACT |
While only four globally important rotavirus G serotypes (1 to 4)
have been documented, many studies suggest that serotype G9 viruses may
be widely distributed and more important than previously recognized. We
have evaluated 10 serotype G9 rotavirus-neutralizing monoclonal
antibodies (MAbs) directed to VP7, which bound by direct enzyme
immunoassay (EIA) to P1A[8], G9 rotaviruses F45, WI61, and AU32, for
their ability to recognize the New Delhi G9 rotavirus 116E. Only one
MAb (MAb F45:1) bound to P[11], G9 virus 116E to a high titer by EIA.
This MAb was incorporated into an indirect EIA for G serotyping, which
was validated with prototype cultivable human rotaviruses of G types 1 to 4 and 9. The EIA was compared with genotyping by reverse
transcriptase PCR (RT-PCR) under code for the determination of the G
types of rotaviruses obtained from neonates in New Delhi, India. The
sensitivities of RT-PCR and EIA (after two additional freeze-thaw
cycles) for the typing of G9 rotaviruses were 91 and 86%,
respectively, for 24 culture-adapted rotavirus strains. The untypeable
culture-adapted rotavirus samples also were unreactive with VP7 group
antigen-reactive MAb 60. After two additional freeze-thaw cycles, only
26 of 42 (62%) of stools containing rotavirus typed as G9 by RT-PCR
were positive for G9 rotavirus by EIA. Stools containing rotavirus
untypeable by EIA contained significantly less MAb 60-reactive VP7
antigen (P = 0.0001) than the stools containing
typeable rotavirus. Thus, RT-PCR genotyping was the more sensitive
method for determination of G9 type, but a serotype was readily
determined in rotavirus samples containing MAb 60-reactive VP7 antigen
by an EIA that incorporates MAb F45:1.
 |
INTRODUCTION |
Group A rotaviruses are the major
etiologic agents of severe acute diarrhea in infants and young children
worldwide (33). Infectious virions comprise six structural
proteins in three protein layers enclosing 11 segments of
double-stranded RNA (dsRNA). Rotavirus serotype classification is based
on differences in antigenic determinants that elicit neutralizing
antibodies on the major component of the outer capsid, VP7 (G
serotypes), and the spike protein, VP4 (P serotypes), whose proteolytic
cleavage activates rotavirus infectivity. VP7 is a glycoprotein encoded
by gene segment 7, 8, or 9, whereas VP4 is encoded by gene segment 4, so that VP7 (G) and VP4 (P) serotypes can segregate independently
(30). Nucleotide sequence analysis of rotavirus variants
selected for resistance to neutralization by VP7-specific monoclonal
antibodies (MAbs) has allowed the definition of six antigenic regions,
regions A to F, on VP7 (8, 16, 17, 34, 35). Apart from
region D (amino acid [aa] 291), all these regions correspond to areas of the VP7 protein that are divergent between serotypes (23, 28). All regions may participate in conformation-dependent neutralization.
Rotavirus serotypes were originally defined by using
cross-neutralization assays with hyperimmune serum, and it was shown subsequently that serotypes so defined relate primarily to VP7 and
correspond to G serotypes (6). P serotypes were defined in
neutralization assays by using hyperimmune antisera raised to
baculovirus-expressed VP4 (24) or to reassortant rotaviruses (29). At least 10 G serotypes (serotypes G1 to G6, G8 to
G10, and G12) and 7 P serotypes (serotypes P1A, P1B, P2A, P3 to P5, and
P8) of human rotaviruses have been found to date. Both G and P
serotypes can now be identified by enzyme immunoassay (EIA) that
incorporates VP7- and VP4-reactive, serotype-specific MAbs (4, 6,
11, 42, 45, 47). However, P serotypes show cross-reactivity more
frequently than G serotypes, making P serotyping by EIA difficult.
Alternative P-typing methods have been developed on the basis of the
degree of amino acid sequence variation in VP4 of rotavirus strains of
different P serotypes. These include hybridization (38),
restriction fragment length polymorphism assay (31), and
reverse transcriptase PCR (RT-PCR) with seminested primers
(21). These techniques are also applicable to G-genotype determination (12, 19, 25, 26). Among human rotaviruses, eight genomic P types (genotypes) which correspond to some of the
described P serotypes have been defined. As the correlation between VP4
(P) serotypes and genotypes is not completely established, both are
used to describe rotaviruses. P genotypes are included within brackets,
whereas P serotypes are open numbers, with letters used to designate
current subtypes. For example, the prototype human rotavirus strain
RV-4 is designated P1A[8], G1 (18). In this paper, the G
types of rotaviruses for which only the G genotype has been determined
also will be indicated with brackets.
Numerous epidemiological studies have shown that G1 rotaviruses
predominate worldwide as a cause severe rotavirus gastroenteritis, with
G2, G3, and G4 strains being responsible for the majority of the
residual disease (22). Most P-genotyping studies have shown
that the rotaviruses of G1, G3, and G4 are P[8] and that the G2
strains are associated with P[4]. When the P serotypes of these G1 to
G4 rotaviruses have been determined, they generally correspond to the
genotype determined or to the P type predicted (4, 6, 42),
so that, in descending order, the predominant rotaviruses that cause
disease are P1A[8] G1, P1A[8] G4, P1B[4] G2, and P1A[8] G3
(22).
Although rotaviruses of the G9 serotype have been found less often than
serotypes G1 to G4, they have been important causes of diarrhea in
India (43), Bangladesh (50), and the United States (44). P1A[8], G9 rotavirus WI61 was isolated in
Philadelphia, Pa., in 1983 and 1984, and viruses of this RNA
electropherotype caused 9% of rotavirus disease at that time
(3). In Japan in 1985 and 1986, 12% of cases of rotavirus
disease in Yamagata (39) and 52% of cases of rotavirus
disease in Osaka (32) were attributed to G9 rotaviruses, of
which F45 (P1A[8], G9) (27) and AU32 (P1A[8], G9)
(40), respectively, are representative. In India in 1993, P[6], G[9] rotaviruses were the most commonly detected type in children with diarrhea (43). P[11], G[9] rotaviruses,
represented by culture-adapted strain 116E (20), and P[6],
G[9] rotaviruses were the predominant strains isolated from neonates
in New Delhi, India, between 1986 and 1993 (12). The G
serotype of 116E was determined to be 9 by cross-neutralization with
hyperimmune antisera, but the G serotypes of the stool viruses were not determined.
The results of these studies raise the question of whether G9
rotaviruses have been underdiagnosed and suggest that inclusion of
G9-specific MAbs in G-serotyping EIA protocols is warranted. MAbs
directed to VP7 of G9 rotaviruses have been derived (34, 37). One panel of 10 MAbs all bound by EIA and neutralized G9 rotavirus strains F45, WI61, and AU32, and the MAbs were mapped to
antigenic regions A, B, C, and F (17, 34, 35). However, an
evaluation of existing MAbs for their utility in EIA for stool rotaviruses has not been performed (34, 37). We therefore tested the panel of 10 G9 MAbs for their ability to react with the G9
rotavirus strain 116E by EIA and neutralization assay and then further
evaluated 3 MAbs for EIA detection of G[9] rotaviruses in culture and
in stools using the New Delhi P[11], G[9] and P[6], G[9] rotaviruses.
 |
MATERIALS AND METHODS |
Viruses.
The following prototype cultivable rotaviruses
whose origins have been described previously (4, 8, 10) were
used for the evaluation of the G9-reactive MAbs for serotyping: human
viruses RV-4 (P1A[8], G1), RV-5 (P1B[4], G2), ST-3 (P2A[6], G4),
Hosokawa (P1A[8], G4), and F45, WI61, and AU32 (P1A[8], G9); simian
virus SA11 (P[2], G3); and porcine virus TFR41 (P2B[7], G4). The
P[11], G9 rotavirus 116E was isolated from a New Delhi neonate
infected asymptomatically (13). Rotaviruses were propagated
in MA 104 cells in the presence of 1 µg of porcine trypsin (Sigma)
per ml following activation with 10 µg of porcine trypsin per ml as
described previously (10). Rotaviruses and mock-infected MA
104 cells (for use as a negative control) were partially purified as
described previously for EIA antigen (4) for use in the
direct and serotyping EIA formats.
A panel of 50 stool samples and 24 culture-adapted rotaviruses isolated
from a separate set of stools from newborn infants at six government
hospitals in New Delhi between 1986 and 1988 and between 1992 and 1993, as well as strains from a longitudinal study (1, 12), were
evaluated. Since the serotype of the viruses in almost all of the
stools and culture-adapted rotaviruses from which the 74 samples were
selected were G[9] by RT-PCR (12), the selection of the
samples for study was random. A few samples with non-G[9] rotavirus
were chosen to serve as controls, and the viruses in these samples were
representative of the small number of non-G[9] rotaviruses present in
this population. G9 rotavirus strain 116E was serotyped by
cross-neutralization with hyperimmune antisera (13) and was
representative of the majority of the New Delhi G9 rotaviruses, which
also were P[11]. A minority of these G9 rotaviruses were P[6]
(12).
MAbs.
The derivation and characterization of the
VP7-specific, rotavirus-neutralizing MAbs and selection of rotavirus
escape mutants with these MAbs have been the subjects of previous
reports (5-11, 17, 34-36). Antibody designation,
immunoglobulin class, and G-serotype specificity are summarized in
Table 1. Antibodies were titrated against
prototype cultivable rotaviruses by using a direct EIA, in which
partially purified virus or cell control antigen was adsorbed to the
solid phase and then serial twofold dilutions of MAbs were added and
allowed to bind to immobilized virus. Bound antibody was detected with
horseradish peroxidase (HRP)-conjugated anti-mouse immunoglobulins
(Silenus, Melbourne, Victoria, Australia) and then with substrate
containing 3,3',5,5'-tetramethylbenzidine (TMB; Sigma Chemical Co., St.
Louis, Mo.) (4, 10, 11). MAb F45:1 was also titrated by the
serotyping EIA format (see below). Neutralization titers of MAbs
against prototype cultivable rotaviruses were determined by fluorescent
focus reduction neutralization (FFN) assay, as described previously
(7).
Serotyping EIA.
The serotyping EIA method for G types 1 to 4 has been described previously (6, 11, 49). It was adapted to
include G9 specificity by the inclusion of rabbit hyperimmune antiserum
raised to F45 rotavirus (11) diluted 1 in 4,000 in
phosphate-buffered saline (PBS; pH 7.4) to coat the solid phase and MAb
F45:1 to detect bound virus. Otherwise, the EIA was performed as
described previously. In brief, for each sample to be tested, wells of
a microtiter plate were coated separately with rabbit hyperimmune antisera to each of rotavirus G types 1 to 4 and 9. Test samples diluted in PBS containing 0.05% (vol/vol) Tween 20 and 2.5% (wt/vol) skim milk powder (PBS-T-SMP) were added, followed by the addition of
purified, serotype-specific MAbs diluted in PBS-T-SMP relative to
ascitic fluid as indicated: RV-4:2 (G1-specific), 1 in 1,000; RV-5:3
(G2-specific), 1 in 4,300; RV-3:1 (G3-specific), 1 in 20,000; ST-3:1
(G4-specific), 1 in 4,500; F45:1, 1 in 10,000; F45:9, 1 in 2,000; and
WI61:1, 1 in 10,000. A VP7-cross-reactive, nonneutralizing MAb, MAb 60 (41, 46), was also included. It was diluted 1 in 2,000 in
PBS-T-SMP and was used to detect the presence of VP7 antigen in wells
coated with antiserum to F45 rotavirus. Bound MAbs were detected by
addition of HRP-conjugated antimouse immunoglobulins and TMB substrate
as described above. Optimal dilutions of reagents were determined by
checkerboard titration.
G typing by RT-PCR.
Genomic dsRNA was extracted from fecal
samples containing rotavirus by the glass powder method
(21). Stocks of rotavirus grown in MA 104 cells were frozen
and thawed three times and were then clarified by low-speed
centrifugation to remove cell debris. The dsRNA in the supernatant was
extracted by the phenol-chloroform method, followed by ethanol
precipitation and glass powder extraction. Rotavirus genotypes were
determined by a one-step RT-PCR amplification method with type-specific
primers, agarose gel electrophoresis, and ethidium bromide staining as
described previously (12). Markers (123-bp ladder; Gibco
BRL, Gaithersburg, Md.) and products amplified from prototype human
rotaviruses possessing G types 1 to 4 and 9 were included for genotype
determination, as described previously (43).
Statistical analysis.
The correlation between MAb EIA
reactivities was examined by the nonparametric two-tailed Spearman
test. The significance of differences in MAb 60 reactivity between
groups of rotavirus samples either typeable or nontypeable by EIA was
assessed by the nonparametric two-tailed Mann-Whitney test.
Significance was set at the 99% level.
 |
RESULTS |
Reactivity of G9 rotavirus-neutralizing MAbs with cultivable
prototype rotaviruses by FFN, direct EIA, and serotyping EIA.
A
panel of 10 MAbs was evaluated for the ability to bind to and
neutralize P[11], G9 virus 116E (Table 1). All MAbs except F45:8
neutralized 116E, and all MAbs bound to 116E, albeit some (F45:6 and
F45:8) bound very weakly. All of the MAbs that mapped to the
A-antigenic region (F45:5, F45:6, F45:7, F45:8, F45:9, and WI61:1) and
one (RV-3:2) of two directed to the B-antigenic region showed lower FFN
and EIA titers with 116E rotavirus than with the other G9 rotaviruses.
MAb F45:2, which mapped to the antigenic F region, showed somewhat
reduced levels of binding by EIA. Only one MAb, MAb F45:1, which mapped
to the C-antigenic region of VP7, neutralized and bound to 116E virus
to a high titer, at levels similar to those obtained with the other G9
rotaviruses tested.
MAb F45:1 was assessed by titration in the G-serotyping EIA format with
10 prototype cultivable rotavirus strains representing G types 1 to 5 and 9 (Table 2). This MAb reacted at the
highest titer with all four G9 rotaviruses, at a medium titer with the G4 strains Hoso and ST-3, and at a very low titer with G1 to G3 and G5
rotaviruses. For use in the serotyping EIA, a single dilution of the
MAb was chosen; the dilution chosen was the highest dilution that gave
the maximum optical density at 450 nm (OD450) with the four
G9 rotaviruses (strains WI61, F45, 116E, and AU32). For MAb F45:1, this
was 1 in 10,000.
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Reactivities of MAbs used to distinguish G types 1 to 4 and 9 by serotyping EIA with a panel of cell
culture-adapted rotaviruses
|
|
In the serotyping EIA (Table 2), all viruses tested reacted with MAb
60, and their OD450s with this MAb showed a significant correlation with their OD450s with the G-typing MAb(s) that
gave a positive result(s) (r = 0.7781, P = 0.01).
The G1 to G5 rotaviruses all reacted with the G1- to G4-typing MAbs in
the expected pattern. These results showed that the virus samples
contained native VP7 in sufficient quantity to be serotypeable. MAb
F45:1 reacted strongly with all four G9 rotaviruses and the G4 virus
Hosokawa, consistent with its ability to neutralize (34) and
bind to this rotavirus. MAb F45:1 did not detect the other G4 rotavirus
tested, ST-3, probably because the dilution of the purified MAb used (1 in 10,000 relative to ascitic fluid) was only twofold lower than the
endpoint titer of this MAb with ST-3 (1 in 20,000). No reaction of MAb F45:1 with G1, G2, G3, or G5 rotavirus was detected, consistent with
its use at a dilution of 1 in 10,000 in the serotyping EIA.
Comparison of MAb EIA and RT-PCR for determination of G types of
culture-adapted and stool rotaviruses.
The G types of 24 rotavirus
strains that were adapted to culture and that were obtained from stools
from New Delhi neonates were determined by RT-PCR and EIA with MAb
F45:1 for the detection of G9 rotaviruses (Table
3). Since MAb F45:1 binds to some G4 rotaviruses at the dilution used in the serotyping EIA, we used a
correlation of reactivity with MAb F45:1 and failure to react with the
G4-specific MAb ST-3:1 as the criterion for assignment of type G9. All
the strains that were G[9] were also P[11] by RT-PCR. Identical
results were obtained by the two VP7 typing methods for 14 (58%) of
strains (13 G9 strains and 1 G3 strain). When either method detected a
mixture of G9 virus with another type (n = 3), the
non-G9 type was not detected in the alternative system. Neither of the
viruses typed as G[2] by RT-PCR was typeable by EIA, and neither
reacted with MAb 60. Three strains that were typed as G[9] by RT-PCR
were untypeable by EIA. Conversely, two viruses that were typed as G9
by EIA were untypeable by RT-PCR. Thus, of the 21 strains typed as G9
by either method, 19 (91%) were typed by RT-PCR and 18 (86%) were
typed by EIA, so the two methods had similar sensitivities. The
relation between the levels of reaction of MAb 60 and the appropriate
type-specific MAb with the prototype cultivable rotaviruses listed in
Table 2 (n = 10) and the culture-adapted New Delhi
viruses which were typeable by EIA (n = 19; Table 3)
was examined (Fig. 1). These MAb
reactivities showed a significant correlation (r = 0.85;
P < 0.0001), suggesting that the reactivity of a sample of
cultivable virus with MAb 60 shows that it contains sufficient native
VP7 for successful serotyping by EIA.
View this table:
[in this window]
[in a new window]
|
TABLE 3.
Comparison of MAb serotyping EIA and RT-PCR for
determination of G9 types of cell culture-adapted human rotaviruses
|
|

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 1.
Relation between levels of typing MAb and MAb 60 reactivities with 25 cultivable human rotaviruses of G serotypes 1 to 4 and 9. The OD450 was obtained by the serotyping EIA. The
sigmoidal curve of best fit shown was determined by regression analysis
(r2 = 0.89).
|
|
The G types of rotavirus detectable in 50 stool specimens collected
from New Delhi neonates were determined by RT-PCR and EIA with MAb
F45:1 (Table 4). As for the cultivable
viruses, when either method detected a mixture of G9 virus with another type (n = 2), the non-G9 type was not detected in the
alternative system. The single G3 rotavirus was typed by both methods,
and four stool samples contained virus untypeable by either method. Of
the 42 stool samples in which G9 rotavirus was detected by either
method, all were positive by RT-PCR, but only 26 (62%) were positive
by EIA. All the stool extracts containing viral antigen typeable by EIA
also reacted with MAb 60. However, only 12 (63%) of the stool
extracts, which contained rotavirus that was typeable or not, that were
tested by RT-PCR and whose viruses were not typeable by EIA
(n = 19) contained VP7 antigen detectable with MAb 60. The relation between the level of virus reactivity with MAb 60 and
success in obtaining a G serotype by EIA (Fig. 2) suggests that MAb 60 reactivity is a
marker for the ability to type VP7 by EIA in stools and virus stocks.
Virus reactive with this antibody was G typeable by EIA significantly
more often both in stools (P = 0.0001) and in culture
(P = 0.008).
View this table:
[in this window]
[in a new window]
|
TABLE 4.
Comparison of MAb serotyping EIA and RT-PCR for
determination of G9 type in stool extracts containing
human rotaviruses
|
|

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 2.
Relation of level of MAb 60 reactivity to serotyping MAb
reactivity in the EIA. cc, cell culture-adapted rotavirus; stool,
rotavirus-positive stool sample; NT, not typeable by G-serotyping EIA;
T, typeable by G-serotyping EIA. Horizontal bars indicate median values
for each group. The positive-negative cutoff for MAb 60 reactivity by
EIA is shown with a dashed line.
|
|
Since MAb F45:1 detected only 62% of stool rotaviruses genotyped as 9 by RT-PCR, two additional G9-reactive MAbs, MAbs WI61:1 and F45:9, were
evaluated. These were chosen on the basis of their consistently high
EIA titers to cultivable G9 rotaviruses, including strain 116E (Table
1). MAb F45:5 was not evaluated because of its low affinity in the EIA.
As shown in Table 5, MAb WI61:1 typed 14 (61%) of the 23 stool G9 rotaviruses typed by MAb F45:1, whereas MAb
F45:9 typed only 2 (9%) of these stool viruses. MAb WI61:1 also typed
as G9 5 of 16 (31%) of stool viruses that contained G9 virus by RT-PCR
but that did not react with MAb F45:1. Used individually, MAb WI61:1
and MAb F45:9 were not as suitable as MAb F45:1 for G9 rotavirus typing
for these stool samples. However, inclusion of MAb WI61:1 as well as
MAb F45:1 for G9 typing increased the overall typing rate by EIA from
62 to 74%, although two (6%) of the reactions with MAb WI61:1
(n = 32) may have been false positive since no MAb
60-reactive antigen was detected in these samples. Interpretation of
results obtained with MAb WI61:1 may be complicated by the
cross-reactivity of this MAb with G5 and G8 rotaviruses (Table 1).
View this table:
[in this window]
[in a new window]
|
TABLE 5.
Comparison of G9-reactive MAbs F45:1, WI61:1, and F45:9
for determination of G9 type in stool extracts containing
human rotaviruses
|
|
 |
DISCUSSION |
We have demonstrated that MAb F45:1 can be used to serotype G9
rotaviruses by EIA. It was found that both culture-adapted and fecal
rotaviruses assigned to serotype G9 by RT-PCR genotyping were also G9
by EIA, thus confirming that serotype G9 rotaviruses were a common
cause of rotavirus infections of neonates in India in 1993. This study
is especially timely because of the recent detection of G9 rotavirus in
multiple cities of the United States and in Bangladesh, suggesting with
earlier studies that G9 strains probably have a global distribution and
may be much more prevalent than was previously believed (13, 33,
39, 43, 44, 50). In view of the recent introduction of the
tetravalent rhesus-human reassortant rotavirus vaccine (which contains
the VP7 antigens of serotypes G1 to G4 only) in the United States, it
will be crucial to conduct large-scale surveillance studies for G9
rotavirus to help determine the effectiveness of the vaccine against
these novel strains. Such studies would be facilitated by the
availability of EIA-based methods for the serotyping of rotaviruses
directly from fecal specimens, as genotyping by RT-PCR is an indirect
measure of virus serotype.
It was interesting that of 10 G9-neutralizing MAbs, only one proved to
be suitable for detection of all four of the prototype cultivable G9
human rotaviruses by EIA. This was primarily because this was the only
MAb that did not show reduced neutralization and binding titers with
116E compared with those with the three other viruses. These results
suggest that 116E differs antigenically from the three other G9
rotaviruses at positions that affect VP7 at antigenic regions A, B, and
F but not region C. It is possible that 116E is a G9 monotype or
subtype (5, 9) different from those of the other G9 strains.
Comparison of the amino acid sequences of VP7 of 116E, WI61, F45, and
AU32 shows that 116E differs from the other G9 viruses at aa 87 (D to
G) and aa 100 (A to I) in antigenic region A and at aa 220 (A to T) and
aa 221 (S to N) in antigenic region C. Although MAb-resistant variants
with mutations at these positions have not been selected in any
rotavirus strain studied, these changes may affect antigenicity.
Rotavirus 116E also differs from WI61 and F45 in region B at aa 145 (D
to T). This produces a new potential glycosylation site, which, if
used, could explain the reduced binding of the B-region MAbs to 116E. A
change in region F of 116E at aa 242 (T to N) may also explain the
reduced binding of MAb F45:2 to 116E.
It is also possible that differences in other structural proteins,
particularly VP4, affect the antigenicity of strain 116E VP7.
Interactions between VP4 and VP7 of heterologous parent origin affected
the presentation of a VP4 epitope (2), and the position of
amino acid mutations in the VP7 of antigenic variants was altered in
reassortants heterologous for the remaining 10 genes (35). The interaction between VP4 and VP7 of murine P10[16], G3 rotavirus EW (18) was likely to have blocked or altered antigenic A-
and C-region epitopes of VP7 (15). The conformation of the A
and C regions of herpes simplex virus type 1-expressed VP7 appeared to
be dependent on interaction with other rotaviral proteins
(14). Since strain 116E has a P serotype (P8[11])
different from that for strains WI61, F45, and AU32 (P1A[8]), this
difference represents another possible explanation for its altered
reactivity to VP7 MAbs (18, 20).
The sensitivities of EIA and RT-PCR for determination of the G9
serotype were similar for cultivable rotaviruses, but EIA detected only
62% of stool rotaviruses genotyped as 9 by RT-PCR. RT-PCR has shown
greater sensitivity than EIA for determination of human rotavirus G
types 1 to 4 in previous studies (48, 51). Reaction of the
VP7 group antigen-specific MAb 60 with virus-containing samples
correlated with the ability to serotype the virus by EIA with MAb F45:1
and the MAbs specific for G types 1 to 4 and with the level of typing
MAb binding. It therefore appears that degradation of VP7 antigen was a
major factor in the loss of typing ability by EIA. This has been
reported previously by use of this assay for typing of G1 to G4
rotaviruses (6, 11, 49). Both cultivable and stool rotavirus
samples were frozen and thawed two extra times after RT-PCR analysis
before EIA typing was performed. It is likely that the exposure of
stool (but not cultivable) rotavirus to proteolytic enzymes during
these freeze-thaw cycles was responsible for the higher levels of VP7
degradation for virus in stools compared with those for culture-adapted
rotaviruses. Inclusion of MAb 60 or a similar antibody in rotavirus
G-serotyping EIA protocols will help in the differentiation between the
inability to type the strain because of VP7 degradation and a lack of a
reaction because a novel serotype or monotype is present
(9).
One New Delhi culture-adapted rotavirus and one rotavirus-positive
stool sample reacted strongly and several other samples had slightly
elevated OD450 readings with G4-typing MAb ST-3:1 by EIA.
By RT-PCR, these samples contained only G9 rotavirus. The presence of a
mixture of rotaviruses in these samples could not be confirmed by RNA
electropherotyping or subgroup analysis (data not shown). It is thus
possible that MAb ST-3:1 may cross-react with some G9 rotaviruses,
although no significant cross-reaction was found with prototype G9
strains 116E, F45, WI61, and AU32. By EIA with this MAb these viruses
showed slightly elevated OD450 readings which were well
below the positive-negative cutoff. A significant G-serotype
cross-reaction with this MAb has not been observed previously (4,
6, 11, 49). It will be important to evaluate this possible G4-G9
cross-reactivity in further studies of G9 rotavirus strains,
particularly with culture-adapted rotaviruses that bind to both MAb
ST-3:1 and MAb F45:1. Neutralization-resistant variants of ST-3 virus
selected with MAb ST-3:1 showed an amino acid mutation in the
A-antigenic region at position 94 (Ser-Asn) (9). If MAb
ST3:1 is cross-reactive with type G9 strains, it may be due to the
close homology in the A-antigenic region of VP7 between G4 and G9
strains. Rotaviruses 116E, F45, WI61, and AU32 differ from ST-3 in the
A region only at position 94 (Ser-Gly), and since
neutralization-resistant variants of ST-3 selected with MAb ST-3:1 also
have a single mutation in VP7 at the same position, then G4-G9
cross-reactivity would be the most likely one for MAb ST-3:1 to exhibit.
The importance of the epitope specificity of MAbs used for rotavirus
serotyping by EIA is also highlighted by our comparison of MAbs F45:1,
WI61:1, and MAb F45:9 for the typing of G9 rotaviruses in stools. All
three MAbs showed different reactivity patterns. Of the two A-antigenic
region MAbs, WI61:1 and F45:9, only WI61:1 reacted specifically with a
significant number of stool specimens. The EIA reactivity of this MAb
overlapped that of MAb F45:1, but it also detected G9 virus in some
additional stool samples, including two that were not reactive with MAb
60 by EIA. Should this reactivity prove to be specific for G9
rotaviruses, the use of a combination of MAbs F45:1 and WI61:1 may
improve the sensitivity of EIA for the detection of G9 rotavirus in
stool samples. In addition, other G9 MAbs, such as F45:9, bound to
strain 116E at a low titer and barely detected this virus (or G9
rotaviruses in stools) when it was used as a detector antibody in the
standard EIA format. Evaluation of these MAbs or hyperimmune antiserum
to 116E as capture antibodies might also improve the sensitivity of
this assay.
Our findings with Indian neonates need to be extended by evaluation of
this panel of MAbs for EIA serotyping of G9 rotavirus-containing fecal
samples collected in other locations and at other times from both
neonates and older children. It will be of special interest to analyze
the G9 strains which have been detected recently in the United States,
as the introduction of a universal vaccination campaign against
rotavirus with the tetravalent rhesus-human reassortant rotavirus
vaccine makes it imperative that the effectiveness of this vaccine
against type G9 be understood.
The G serotypes of rotaviruses in stools are most easily and
inexpensively determined by an EIA with MAbs. However, RT-PCR is
particularly useful for obtaining a rotavirus G genotype in the smaller
number of stool samples that contain virus that cannot be typed by EIA.
As shown in this study, use of a combination of these methods is
advisable to combine maximum sensitivity (RT-PCR) and direct serotype
determination (MAb EIA) for the typing of G9 rotaviruses in stools.
 |
ACKNOWLEDGMENTS |
We are grateful to John Tam and Harry Greenberg for provision of
MAb 60.
This project was supported by project grants 940315 and 980635 from the
National Health and Medical Research Council of Australia and by grants
from the Indo-U.S. Vaccine Action Program and the National Vaccine Program.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology and Immunology, The University of Melbourne, Royal Parade, Parkville 3052, Victoria, Australia. Phone: 61 3 9344 8823. Fax: 61 3 9347 1540. E-mail:
b.coulson{at}microbiology.unimelb.edu.au.
 |
REFERENCES |
| 1.
|
Bhan, M. K.,
J. F. Lew,
S. Sazawal,
B. K. Das,
J. R. Gentsch, and R. I. Glass.
1993.
Protection conferred by neonatal rotavirus infection against subsequent rotavirus diarrhea.
J. Infect. Dis.
168:282-287[Medline].
|
| 2.
|
Chen, D. Y.,
M. K. Estes, and R. F. Ramig.
1992.
Specific interactions between rotavirus outer capsid proteins VP4 and VP7 determine expression of a cross-reactive, neutralizing VP4-specific epitope.
J. Virol.
66:432-439[Abstract/Free Full Text].
|
| 3.
|
Clark, H. F.,
Y. Hoshino,
L. M. Bell,
J. Groff,
G. Hess,
P. Bachman, and P. A. Offit.
1987.
Rotavirus isolate WI61 representing a presumptive new human serotype.
J. Clin. Microbiol.
25:1757-1762[Abstract/Free Full Text].
|
| 4.
|
Coulson, B. S.
1993.
Typing of human rotavirus VP4 by an enzyme immunoassay using monoclonal antibodies.
J. Clin. Microbiol.
31:1-8[Abstract/Free Full Text].
|
| 5.
|
Coulson, B. S.
1987.
Variation in neutralization epitopes of human rotaviruses in relation to genomic RNA polymorphism.
Virology
159:209-216[Medline].
|
| 6.
|
Coulson, B. S.
1996.
VP4 and VP7 typing using monoclonal antibodies.
Arch. Virol. Suppl.
12:113-118[Medline].
|
| 7.
|
Coulson, B. S.,
K. J. Fowler,
R. F. Bishop, and R. G. Cotton.
1985.
Neutralizing monoclonal antibodies to human rotavirus and indications of antigenic drift among strains from neonates.
J. Virol.
54:14-20[Abstract/Free Full Text].
|
| 8.
|
Coulson, B. S., and C. Kirkwood.
1991.
Relation of VP7 amino acid sequence to monoclonal antibody neutralization of rotavirus and rotavirus monotype.
J. Virol.
65:5968-5974[Abstract/Free Full Text].
|
| 9.
|
Coulson, B. S.,
C. D. Kirkwood,
P. J. Masendycz,
R. F. Bishop, and G. Gerna.
1996.
Amino acids involved in distinguishing between monotypes of rotavirus G serotypes 2 and 4.
J. Gen. Virol.
77:239-245[Abstract/Free Full Text].
|
| 10.
|
Coulson, B. S.,
J. M. Tursi,
W. J. McAdam, and R. F. Bishop.
1986.
Derivation of neutralizing monoclonal antibodies to human rotaviruses and evidence that an immunodominant neutralization site is shared between serotypes 1 and 3.
Virology
154:302-312[Medline].
|
| 11.
|
Coulson, B. S.,
L. E. Unicomb,
G. A. Pitson, and R. F. Bishop.
1987.
Simple and specific enzyme immunoassay using monoclonal antibodies for serotyping human rotaviruses.
J. Clin. Microbiol.
25:509-515[Abstract/Free Full Text].
|
| 12.
|
Das, B. K.,
J. R. Gentsch,
H. G. Cicirello,
P. A. Woods,
A. Gupta,
M. Ramachandran,
R. Kumar,
M. K. Bhan, and R. I. Glass.
1994.
Characterization of rotavirus strains from newborns in New Delhi, India.
J. Clin. Microbiol.
32:1820-1822[Abstract/Free Full Text].
|
| 13.
|
Das, B. K.,
J. R. Gentsch,
Y. Hoshino,
S. Ishida,
O. Nakagomi,
M. K. Bhan,
R. Kumar, and R. I. Glass.
1993.
Characterization of the G serotype and genogroup of New Delhi newborn rotavirus strain 116E.
Virology
197:99-107[Medline].
|
| 14.
|
Dormitzer, P. R.,
D. Y. Ho,
E. R. Mackow,
E. S. Mocarski, and H. B. Greenberg.
1992.
Neutralizing epitopes on herpes simplex virus-1-expressed rotavirus VP7 are dependent on coexpression of other rotavirus proteins.
Virology
187:18-32[Medline].
|
| 15.
|
Dunn, S. J.,
J. W. Burns,
T. L. Cross,
P. T. Vo,
R. L. Ward,
M. Bremont, and H. B. Greenberg.
1994.
Comparison of VP4 and VP7 of five murine rotavirus strains.
Virology
203:250-259[Medline].
|
| 16.
|
Dunn, S. J.,
R. L. Ward,
M. M. McNeal,
T. L. Cross, and H. B. Greenberg.
1993.
Identification of a new neutralization epitope on VP7 of human serotype 2 rotavirus and evidence for electropherotype differences caused by single nucleotide substitutions.
Virology
197:397-404[Medline].
|
| 17.
|
Dyall Smith, M. L.,
I. Lazdins,
G. W. Tregear, and I. H. Holmes.
1986.
Location of the major antigenic sites involved in rotavirus serotype-specific neutralization.
Proc. Natl. Acad. Sci. USA
83:3465-3468[Abstract/Free Full Text].
|
| 18.
|
Estes, M. K.
1996.
Rotaviruses and their replication, p. 1625-1655.
In
B. N. Fields, D. M. Knipe, P. M. Howley, et al. (ed.), Fields virology, 3rd ed., vol. 2. Lippincott-Raven Publishers, Philadelphia, Pa.
|
| 19.
|
Flores, J.,
J. Sears,
I. Perez-Schael,
L. White,
D. Garcia,
C. Lanata, and A. Z. Kapikian.
1990.
Identification of human rotavirus serotype by hybridization to polymerase chain reaction-generated probes derived from a hyperdivergent region of the gene encoding outer capsid protein VP7.
J. Virol.
64:4021-4024[Abstract/Free Full Text].
|
| 20.
|
Gentsch, J. R.,
B. K. Das,
B. Jiang,
M. K. Bhan, and R. I. Glass.
1993.
Similarity of the VP4 protein of human rotavirus strain 116E to that of the bovine B223 strain.
Virology
194:424-430[Medline].
|
| 21.
|
Gentsch, J. R.,
R. I. Glass,
P. Woods,
V. Gouvea,
M. Gorziglia,
J. Flores,
B. K. Das, and M. K. Bhan.
1992.
Identification of group A rotavirus gene 4 types by polymerase chain reaction.
J. Clin. Microbiol.
30:1365-1373[Abstract/Free Full Text].
|
| 22.
|
Gentsch, J. R.,
P. A. Woods,
M. Ramachandran,
B. K. Das,
J. P. Leite,
A. Alfieri,
R. Kumar,
M. K. Bhan, and R. I. Glass.
1996.
Review of G and P typing results from a global collection of rotavirus strains: implications for vaccine development.
J. Infect. Dis.
174:S30-S36.
|
| 23.
|
Glass, R. I.,
J. Keith,
O. Nakagomi,
T. Nakagomi,
J. Askaa,
A. Z. Kapikian,
R. M. Chanock, and J. Flores.
1985.
Nucleotide sequence of the structural glycoprotein VP7 gene of Nebraska calf diarrhea virus rotavirus: comparison with homologous genes from four strains of human and animal rotaviruses.
Virology
141:292-298[Medline].
|
| 24.
|
Gorziglia, M.,
G. Larralde,
A. Z. Kapikian, and R. M. Chanock.
1990.
Antigenic relationships among human rotaviruses as determined by outer capsid protein VP4.
Proc. Natl. Acad. Sci. USA
87:7155-7159[Abstract/Free Full Text].
|
| 25.
|
Gouvea, V.,
R. I. Glass,
P. Woods,
K. Taniguchi,
H. F. Clark,
B. Forrester, and Z. Y. Fang.
1990.
Polymerase chain reaction amplification and typing of rotavirus nucleic acid from stool specimens.
J. Clin. Microbiol.
28:276-282[Abstract/Free Full Text].
|
| 26.
|
Gouvea, V.,
C. Ramirez,
B. Li,
N. Santos,
L. Saif,
H. F. Clark, and Y. Hoshino.
1993.
Restriction endonuclease analysis of the vp7 genes of human and animal rotaviruses.
J. Clin. Microbiol.
31:917-923[Abstract/Free Full Text].
|
| 27.
|
Green, K. Y.,
Y. Hoshino, and N. Ikegami.
1989.
Sequence analysis of the gene encoding the serotype-specific glycoprotein (VP7) of two new human rotavirus serotypes.
Virology
168:429-433[Medline].
|
| 28.
|
Green, K. Y.,
K. Midthun,
M. Gorziglia,
Y. Hoshino,
A. Z. Kapikian,
R. M. Chanock, and J. Flores.
1987.
Comparison of the amino acid sequences of the major neutralization protein of four human rotavirus serotypes.
Virology
161:153-159[Medline].
|
| 29.
|
Hoshino, Y., and A. Z. Kapikian.
1994.
Rotavirus antigens.
Curr. Top. Microbiol. Immunol.
185:179-227[Medline].
|
| 30.
|
Hoshino, Y.,
M. M. Sereno,
K. Midthun,
J. Flores,
A. Z. Kapikian, and R. M. Chanock.
1985.
Independent segregation of two antigenic specificities (VP3 and VP7) involved in neutralization of rotavirus infectivity.
Proc. Natl. Acad. Sci. USA
82:8701-8704[Abstract/Free Full Text].
|
| 31.
|
Iizuka, M.,
M. Chiba,
O. Masamune,
G. Gerna, and O. Nakagomi.
1993.
Molecular characterization of human rotavirus VP4 genes by polymerase chain reaction and restriction fragment length polymorphism assay.
Microbiol. Immunol.
37:729-735[Medline].
|
| 32.
|
Ikegami, N.,
K. Akatani,
T. Hosaka, and H. Ushijima.
1987.
Prevalence of a new serotype of group A human rotaviruses in Japan, abstr. R11.29, p. 113.
In
Program and abstracts of the VII International Congress of Virology. National Research Council of Canada, Ottawa, Ontario, Canada.
|
| 33.
|
Kapikian, A. Z., and R. M. Chanock.
1996.
Rotaviruses, p. 1657-1708.
In
B. N. Fields, D. M. Knipe, P. M. Howley, et al. (ed.), Fields virology, 3rd ed., vol. 2. Lippincott-Raven Publishers, Philadelphia, Pa.
|
| 34.
|
Kirkwood, C.,
P. J. Masendycz, and B. S. Coulson.
1993.
Characteristics and location of cross-reactive and serotype-specific neutralization sites on VP7 of human G type 9 rotaviruses.
Virology
196:79-88[Medline].
|
| 35.
|
Lazdins, I.,
B. S. Coulson,
C. Kirkwood,
M. Dyall Smith,
P. J. Masendycz,
S. Sonza, and I. H. Holmes.
1995.
Rotavirus antigenicity is affected by the genetic context and glycosylation of VP7.
Virology
209:80-89[Medline].
|
| 36.
|
Lazdins, I.,
S. Sonza,
M. L. Dyall Smith,
B. S. Coulson, and I. H. Holmes.
1985.
Demonstration of an immunodominant neutralization site by analysis of antigenic variants of SA11 rotavirus.
J. Virol.
56:317-319[Abstract/Free Full Text].
|
| 37.
|
Midthun, K.,
J. Valdesuso,
A. Z. Kapikian,
Y. Hoshino, and K. Y. Green.
1989.
Identification of serotype 9 human rotavirus by enzyme-linked immunosorbent assay with monoclonal antibodies.
J. Clin. Microbiol.
27:2112-2114[Abstract/Free Full Text].
|
| 38.
|
Nakagomi, O.,
H. Oyamada, and T. Nakagomi.
1989.
Use of alkaline Northern blot hybridization for the identification of genetic relatedness of the fourth gene of rotaviruses.
Mol. Cell. Probes
3:263-271[Medline].
|
| 39.
|
Nakagomi, T.,
K. Akatani,
N. Ikegami,
N. Katsushima, and O. Nakagomi.
1988.
Occurrence of changes in human rotavirus serotypes with concurrent changes in genomic RNA electropherotypes.
J. Clin. Microbiol.
26:2586-2592[Abstract/Free Full Text].
|
| 40.
|
Nakagomi, T.,
A. Ohshima,
K. Akatani,
N. Ikegami,
N. Katsushima, and O. Nakagomi.
1990.
Isolation and molecular characterization of a serotype 9 human rotavirus strain.
Microbiol. Immunol.
34:77-82[Medline].
|
| 41.
|
Noel, J. S.,
G. M. Beards, and W. D. Cubitt.
1991.
Epidemiological survey of human rotavirus serotypes and electropherotypes in young children admitted to two children's hospitals in northeast London from 1984 to 1990.
J. Clin. Microbiol.
29:2213-2219[Abstract/Free Full Text].
|
| 42.
|
Padilla-Noriega, L.,
M. Mendez-Toss,
G. Menchaca,
J. F. Contreras,
P. Romero-Guido,
F. I. Puerto,
H. Guiscarfe,
F. Mota,
I. Herrera,
R. Cedillo,
O. Munoz,
J. Calva,
M. De Lourdes Guerrero,
B. S. Coulson,
H. B. Greenberg,
S. Lopez, and C. F. Arias.
1998.
Antigenic and genomic diversity of human rotavirus VP4 in two consecutive epidemic seasons in Mexico.
J. Clin. Microbiol.
36:1688-1692[Abstract/Free Full Text].
|
| 43.
|
Ramachandran, M.,
B. K. Das,
A. Vij,
R. Kumar,
S. S. Bhambal,
N. Kesari,
H. Rawat,
L. Bahl,
S. Thakur,
P. A. Woods,
R. I. Glass,
M. K. Bhan, and J. R. Gentsch.
1996.
Unusual diversity of human rotavirus G and P genotypes in India.
J. Clin. Microbiol.
34:436-439[Abstract].
|
| 44.
|
Ramachandran, M.,
J. R. Gentsch,
U. D. Parashar,
S. Jin,
P. A. Woods,
J. L. Holmes,
C. D. Kirkwood,
R. F. Bishop,
H. B. Greenberg,
S. Urasawa,
G. Gerna,
B. S. Coulson,
K. Taniguchi,
J. S. Bresee,
R. I. Glass, and the National Rotavirus Strain Surveillance System Collaborating Laboratories.
1998.
Detection and characterization of novel rotavirus strains in the United States.
J. Clin. Microbiol.
36:3223-3229[Abstract/Free Full Text].
|
| 45.
|
Shaw, R. D.,
D. L. Stoner-Ma,
M. K. Estes, and H. B. Greenberg.
1985.
Specific enzyme-linked immunoassay for rotavirus serotypes 1 and 3.
J. Clin. Microbiol.
22:286-291[Abstract/Free Full Text].
|
| 46.
|
Shaw, R. D.,
P. T. Vo,
P. A. Offit,
B. S. Coulson, and H. B. Greenberg.
1986.
Antigenic mapping of the surface proteins of rhesus rotavirus.
Virology
155:434-451[Medline].
|
| 47.
|
Taniguchi, K.,
T. Urasawa,
Y. Morita,
H. B. Greenberg, and S. Urasawa.
1987.
Direct serotyping of human rotavirus in stools by an enzyme-linked immunosorbent assay using serotype 1-, 2-, 3-, and 4-specific monoclonal antibodies to VP7.
J. Infect. Dis.
155:1159-1166[Medline].
|
| 48.
|
Taniguchi, K.,
F. Wakasugi,
Y. Pongsuwanna,
T. Urasawa,
S. Ukae,
S. Chiba, and S. Urasawa.
1992.
Identification of human and bovine rotavirus serotypes by polymerase chain reaction.
Epidemiol. Infect.
109:303-312[Medline].
|
| 49.
|
Unicomb, L. E.,
B. S. Coulson, and R. F. Bishop.
1989.
Experience with an enzyme immunoassay for serotyping human group A rotaviruses.
J. Clin. Microbiol.
27:586-588[Abstract/Free Full Text].
|
| 50.
|
Unicomb, L. E.,
G. Podder,
J. R. Gentsch,
K. Z. Hasan,
A. S. G. Faruque,
M. J. Albert, and R. I. Glass.
1999.
Evidence of high-frequency genomic reassortment of group A rotavirus strains in Bangladesh: emergence of type G9 in 1995.
J. Clin. Microbiol.
37:1885-1891[Abstract/Free Full Text].
|
| 51.
|
Ushijima, H.,
H. Koike,
A. Mukoyama,
A. Hasegawa,
S. Nishimura, and J. Gentsch.
1992.
Detection and serotyping of rotaviruses in stool specimens by using reverse transcription and polymerase chain reaction amplification.
J. Med. Virol.
38:292-297[Medline]. (Erratum, 44:165, 1994.)
|
Journal of Clinical Microbiology, October 1999, p. 3187-3193, Vol. 37, No. 10
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
DiStefano, D. J., Kraiouchkine, N., Mallette, L., Maliga, M., Kulnis, G., Keller, P. M., Clark, H. F., Shaw, A. R.
(2005). Novel Rotavirus VP7 Typing Assay Using a One-Step Reverse Transcriptase PCR Protocol and Product Sequencing and Utility of the Assay for Epidemiological Studies and Strain Characterization, Including Serotype Subgroup Analysis. J. Clin. Microbiol.
43: 5876-5880
[Abstract]
[Full Text]
-
Santos, N., Volotao, E. M., Soares, C. C., Campos, G. S., Sardi, S. I., Hoshino, Y.
(2005). Predominance of Rotavirus Genotype G9 during the 1999, 2000, and 2002 Seasons among Hospitalized Children in the City of Salvador, Bahia, Brazil: Implications for Future Vaccine Strategies. J. Clin. Microbiol.
43: 4064-4069
[Abstract]
[Full Text]
-
Arista, S., Giammanco, G. M., De Grazia, S., Colomba, C., Martella, V.
(2005). Genetic Variability among Serotype G4 Italian Human Rotaviruses. J. Clin. Microbiol.
43: 1420-1425
[Abstract]
[Full Text]
-
Hoshino, Y., Jones, R. W., Ross, J., Honma, S., Santos, N., Gentsch, J. R., Kapikian, A. Z.
(2004). Rotavirus Serotype G9 Strains Belonging to VP7 Gene Phylogenetic Sequence Lineage 1 May Be More Suitable for Serotype G9 Vaccine Candidates than Those Belonging to Lineage 2 or 3. J. Virol.
78: 7795-7802
[Abstract]
[Full Text]
-
Kirkwood, C., Bogdanovic-Sakran, N., Palombo, E., Masendycz, P., Bugg, H., Barnes, G., Bishop, R.
(2003). Genetic and Antigenic Characterization of Rotavirus Serotype G9 Strains Isolated in Australia between 1997 and 2001. J. Clin. Microbiol.
41: 3649-3654
[Abstract]
[Full Text]
-
Santos, N., Volotão, E. M., Soares, C. C., Albuquerque, M. C. M., da Silva, F. M., de Carvalho, T. R. B., Pereira, C. F. A., Chizhikov, V., Hoshino, Y.
(2001). Rotavirus Strains Bearing Genotype G9 or P[9] Recovered from Brazilian Children with Diarrhea from 1997 to 1999. J. Clin. Microbiol.
39: 1157-1160
[Abstract]
[Full Text]
-
O'Halloran, F., Lynch, M., Cryan, B., O'Shea, H., Fanning, S.
(2000). Molecular Characterization of Rotavirus in Ireland: Detection of Novel Strains Circulating in the Population. J. Clin. Microbiol.
38: 3370-3374
[Abstract]
[Full Text]